STAT+: Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between
As more emphasis is placed on the value of prescription medicines, a new study found cost-effectiveness analyses were unavailable for many of the medicines that accounted for a large share of Medicare Part D spending in 2016. And more than half of analyses that were conducted failed to meet minimum standards.
Specifically, cost-effectiveness was not studied for 115 of the 250 drugs for which Part D spending was greatest in 2016, the last year for which complete data was available when the study began. Those medicines accounted for 33% of the $146.1 billion in total Part D spending that year, according to the study published in JAMA Network Open.
Continue to STAT+ to read the full story…
